Inhibrx Total Assets 2011-2026 | INBX

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Inhibrx

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
308 M	291 M	150 M	144 M	26.5 M	9.98 M	17.2 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
308 M	9.98 M	135 M

Quarterly Total Assets Inhibrx

2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
289 M	373 M	213 M	254 M	291 M	165 M	193 M	161 M	150 M	129 M	142 M	125 M	144 M	144 M	144 M	144 M	26.5 M	26.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
373 M	26.5 M	173 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	11.2 M	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	35.6 M	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
AstraZeneca PLC AZN	114 B	-	-	$ 96.9 B	Britain
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	92.2 M	-	-	$ 269 M	USA
BiondVax Pharmaceuticals Ltd. BVXV	99.6 M	-	0.74 %	$ 768 M	Israel
Galera Therapeutics GRTX	7.2 M	-	-32.59 %	$ 7.61 M	USA
Midatech Pharma plc MTP	18.2 M	-	-18.52 %	$ 27.3 M	Britain
Esperion Therapeutics ESPR	466 M	$ 3.14	0.16 %	$ 653 M	USA
Eton Pharmaceuticals ETON	92.1 M	$ 34.42	4.65 %	$ 926 M	USA
Forte Biosciences FBRX	82.8 M	$ 20.35	1.4 %	$ 263 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Checkmate Pharmaceuticals CMPI	78.8 M	-	-	$ 231 M	USA
Celyad Oncology SA CYAD	19.7 M	-	-	$ 12.5 M	Belgium
Berkeley Lights BLI	226 M	-	-7.31 %	$ 87 M	USA
Arcturus Therapeutics Holdings ARCT	271 M	$ 6.84	2.17 %	$ 187 M	Israel
Grifols, S.A. GRFS	21.4 B	$ 8.21	4.72 %	$ 5.58 B	Spain
Generation Bio Co. GBIO	231 M	-	-	$ 344 M	USA
IMV IMV	31.3 M	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
BioNTech SE BNTX	22 B	$ 90.48	3.06 %	$ 21.9 B	Germany
Autolus Therapeutics plc AUTL	589 M	$ 1.64	0.61 %	$ 436 M	Britain
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Heron Therapeutics HRTX	256 M	$ 0.85	0.57 %	$ 142 M	USA
Cyclacel Pharmaceuticals CYCCP	8.18 M	-	-4.36 %	$ 27 M	USA
Compugen Ltd. CGEN	157 M	$ 2.74	0.18 %	$ 256 M	Israel
Anika Therapeutics ANIK	190 M	$ 15.15	2.23 %	$ 217 M	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Aeterna Zentaris AEZS	21.4 M	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
Can-Fite BioPharma Ltd. CANF	9.51 M	$ 3.39	4.17 %	$ 5.58 M	Israel
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	10 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Coherus BioSciences CHRS	258 M	$ 1.52	2.7 %	$ 178 M	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	122 M	-	4.14 %	$ 49.1 M	USA
Allakos ALLK	96.6 M	-	-	$ 28.6 M	USA
Arcutis Biotherapeutics ARQT	433 M	$ 20.45	4.9 %	$ 2.6 B	USA
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA